Enforced inactivity is the order of the day at ImmuPharma as it is forced to watch from the sidelines as its US development partner, Cephalon, is devoured by Israeli generic medicines specialist Teva. The Teva raid on Cephalon has created uncertainty as to what happens with the development of Lupuzor, ImmuPharma's treatment for lupus, which was being funded by Cephalon's milestone payments. Management said an update on the programme would happen by the end of the year when the takeover formalities have been completed.
IC TIP:
Buy
at
67p
